(X6) DATE

If continuation sheet 1 of 4

Division of Health Service Regulation STATEMENT OF DEFICIENCIES (X1) PROVIDER/SUPPLIER/CLIA (X2) MULTIPLE CONSTRUCTION (X3) DATE SURVEY AND PLAN OF CORRECTION **IDENTIFICATION NUMBER:** A. BUILDING: COMPLETED B. WING MHL068-102 04/28/2025 NAME OF PROVIDER OR SUPPLIER STREET ADDRESS, CITY, STATE, ZIP CODE **102 PUREFOY ROAD RSI-PUREFOY ROAD** CHAPEL HILL, NC 27514 SUMMARY STATEMENT OF DEFICIENCIES (X4) ID PROVIDER'S PLAN OF CORRECTION ID (X5) COMPLETE (EACH DEFICIENCY MUST BE PRECEDED BY FULL PRÉFIX PREFIX (EACH CORRECTIVE ACTION SHOULD BE TAG REGULATORY OR LSC IDENTIFYING INFORMATION) CROSS-REFERENCED TO THE APPROPRIATE TAG DATE DEFICIENCY) V 000 INITIAL COMMENTS V 000 An annual and follow up survey was completed on April 28, 2025. A deficiency was cited. RECEIVED This facility is licensed for the following service category: 10A NCAC 27G .5600C Supervised Living for Adults with Developmental Disability. This facility is licensed for 6 and has a current census of 6. The survey sample consisted of audits of 3 current clients. V 118 27G .0209 (C) Medication Requirements V 118 All medication certified staff trained at Purefoy will receive supplemental training 10A NCAC 27G .0209 MEDICATION on medication requirements. By 5/15/25. REQUIREMENTS (c) Medication administration: (1) Prescription or non-prescription drugs shall only be administered to a client on the written order of a person authorized by law to prescribe drugs. (2) Medications shall be self-administered by clients only when authorized in writing by the client's physician. (3) Medications, including injections, shall be administered only by licensed persons, or by unlicensed persons trained by a registered nurse. pharmacist or other legally qualified person and privileged to prepare and administer medications. (4) A Medication Administration Record (MAR) of all drugs administered to each client must be kept current. Medications administered shall be recorded immediately after administration. The MAR is to include the following: (A) client's name: (B) name, strength, and quantity of the drug: (C) instructions for administering the drug; (D) date and time the drug is administered; and (E) name or initials of person administering the drug. Division of Health Service Regulation LABORATORY DIRECTOR'S OR PROVIDER/SUPPLIER REPRESENTATIVE'S SIGNATURE

STATE FORM

TITI F

Division of Health Service Regulation (X3) DATE SURVEY (X2) MULTIPLE CONSTRUCTION (X1) PROVIDER/SUPPLIER/CLIA STATEMENT OF DEFICIENCIES COMPLETED IDENTIFICATION NUMBER: AND PLAN OF CORRECTION A. BUILDING: ___ 04/28/2025 B. WING MHL068-102 STREET ADDRESS, CITY, STATE, ZIP CODE NAME OF PROVIDER OR SUPPLIER 102 PUREFOY ROAD **RSI-PUREFOY ROAD** CHAPEL HILL, NC 27514 PROVIDER'S PLAN OF CORRECTION (X5) COMPLETE SUMMARY STATEMENT OF DEFICIENCIES ID (X4) ID PREFIX (EACH CORRECTIVE ACTION SHOULD BE (EACH DEFICIENCY MUST BE PRECEDED BY FULL PREFIX DATE CROSS-REFERENCED TO THE APPROPRIATE REGULATORY OR LSC IDENTIFYING INFORMATION) TAG TAG DEFICIENCY) V 118 V 118 Continued From page 1 (5) Client requests for medication changes or checks shall be recorded and kept with the MAR file followed up by appointment or consultation with a physician. This Rule is not met as evidenced by: Based on record reviews and interviews, the facility failed to keep the MAR current affecting two of three audited clients (#1 and #3). The findings are: Review on 4/23/25 of client #1's record revealed: -Admission date of 2/2/23. -Diagnoses of Mild Intellectual Disability, Epilepsy, Seizure Disorder and Cerebral Palsy. -Physician's order dated 3/25/25 for the following: Polyethylene Glycol Powder 3350 (constipation), mix one capful and drink Olopatadine Sol 0.2 milligrams (mg) (itchy eyes), instill one drop into both eyes once daily Senna plus 8.6-50 mg (constipation), two tablets daily Verapamil 240 mg (high blood pressure), one tablet at bedtime Famotidine 20 mg (acid reflux), one tablet twice daily Review on 4/23/25 of client #1's MARs revealed: March 2025--No staff initials to indicate the medication was administered for the following: Polyethylene Glycol Powder 3350 on 3/8 and 3/9. Olopatadine Sol 0.2 mg on 3/15.

PRINTED: 04/29/2025 FORM APPROVED Division of Health Service Regulation STATEMENT OF DEFICIENCIES (X1) PROVIDER/SUPPLIER/CLIA (X2) MULTIPLE CONSTRUCTION (X3) DATE SURVEY AND PLAN OF CORRECTION **IDENTIFICATION NUMBER:** COMPLETED A. BUILDING: ___ B. WING MHL068-102 04/28/2025 NAME OF PROVIDER OR SUPPLIER STREET ADDRESS, CITY, STATE, ZIP CODE **102 PUREFOY ROAD RSI-PUREFOY ROAD** CHAPEL HILL, NC 27514 SUMMARY STATEMENT OF DEFICIENCIES (X4) ID PROVIDER'S PLAN OF CORRECTION ID (X5) COMPLETE (EACH DEFICIENCY MUST BE PRECEDED BY FULL **PREFIX** PREFIX (EACH CORRECTIVE ACTION SHOULD BE REGULATORY OR LSC IDENTIFYING INFORMATION) TAG CROSS-REFERENCED TO THE APPROPRIATE TAG DATE DEFICIENCY) V 118 | Continued From page 2 V 118 Senna plus 8.6-50 mg on 3/25. Verapamil 240 mg on 3/24 and 3/29. February 2025--No staff initials to indicate the medication was administered for the following: Olopatadine Sol 0.2 mg 2/17. Famotidine 20 mg on 2/5. Review on 4/23/25 of client #3's record revealed: -Admission date of 11/4/03. -Diagnoses of Mild Intellectual Disability, Autistic Disorder, Epilepsy, Gastroesophageal Reflux Disease, Hyperlipidemia and Vitamin D Deficiency. -Physician's order dated 3/24/25 for the following: Ear wax Solution Removal (soften ear wax), instill 5 drops in both ears twice a day for the first 4 days of each month Zeasorb Powder (skin infection), spread topically to both feet 3 times a day Folic Acid 1 mg (folate deficiency), one tablet daily Omeprazole 20 mg (acid reflux), one capsule daily Risperidone 2 mg (bipolar disorder), one half tablet three times daily Depakote 250 mg (epilepsy), 2 tablets three times daily Review on 4/23/25 of client #3's MARs revealed:

Division of Health Service Regulation

April 2025-

-No staff initials to indicate the medication was

Zeasorb Powder on 4/4, 4/6 and 4/20 4pm doses.

Risperidone 2 mg on 4/4, 4/6, 4/11 and 4/20 4pm

Folic Acid 1 mg on 4/16, 4/18 and 4/19.

administered for the following: Ear wax Solution on 4/1 both doses.

Omeprazole 20 mg on 4/16.

Division of Health Service Regulation (X3) DATE SURVEY (X1) PROVIDER/SUPPLIER/CLIA (X2) MULTIPLE CONSTRUCTION STATEMENT OF DEFICIENCIES COMPLETED IDENTIFICATION NUMBER: AND PLAN OF CORRECTION A. BUILDING: __ 04/28/2025 B. WING MHL068-102 STREET ADDRESS, CITY, STATE, ZIP CODE NAME OF PROVIDER OR SUPPLIER 102 PUREFOY ROAD **RSI-PUREFOY ROAD** CHAPEL HILL, NC 27514 PROVIDER'S PLAN OF CORRECTION (X5) COMPLETE SUMMARY STATEMENT OF DEFICIENCIES (X4) ID PREFIX (EACH CORRECTIVE ACTION SHOULD BE (EACH DEFICIENCY MUST BE PRECEDED BY FULL **PREFIX** CROSS-REFERENCED TO THE APPROPRIATE DATE REGULATORY OR LSC IDENTIFYING INFORMATION) TAG TAG DEFICIENCY) V 118 V 118 Continued From page 3 Depakote 250 mg on 4/16 8am dose; 4/4, 4/6, 4/11, 4/19 and 4/20 4pm doses. March 2025--No staff initials to indicate the medication was administered for the following: Ear wax Solution on 3/2 8am dose. Zeasorb Powder on 3/4 4pm dose. February 2025--No staff initials to indicate the medication was administered for the following: Depakote 250 mg on 2/12 8am dose Interview on 4/23/25 with staff #1 revealed: -Clients #1 and #3 received their medication. -Staff forgot to sign off on their MARs. -He confirmed the MAR was not kept current for clients #1 and #3. Interview on 4/23/25 with the Supervisor of Support Services revealed: -They had some issues with staff not documenting the MARs after administering medication to clients. -There were no issues with clients getting their medication. -"The medication count is correct, staff just struggle to remember to put their initials on the -He confirmed the MAR was not kept current for clients #1 and #3. This deficiency constitutes a re-cited deficiency and must be corrected within 30 days.

DEDX11